ISSLEDOVANIE SAVOR: OTKRYTIE NOVOY EPOKhI BEZOPASNOY FARMAKOTERAPII SAKhARNOGO DIABETA 2 TIPA
- Authors: Yuryatin A.A1
-
Affiliations:
- Issue: No 5 (2014)
- Pages: 32-35
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286723
- ID: 286723
Cite item
Open Access
Access granted
Abstract
In the history of diabetology, there were many treatment methods that, when studied more extensively, turned out to be not sufficiently safe: synthalin, phenphormin, the list can be continued. The last story with rosiglitazone made the FDA implement new unprecedented requirements for the evidence base for hypoglycemic pharmacological agents being registered on the territory of the USA. The huge study SAVOR, which results were published in September 2013, became the first reliable confirmation of the safety of a DPP-4 inhibitor available on the Russian market. Saxagliptin was studied in a double-blind placebo-controlled study on 16 492 type-2 diabetes mellitus patients with high cardiovascular risk and wide HbA1c range (6.5-11.9 %). After two years of follow-up, the primary endpoint’s cardiovascular risk ratio was 1.00 (95 % CI 0.89-1.12). Thus, in Russia currently saxagliptin is the DPP-4 inhibitor with the most confirmed cardiovascular safety.
Full Text
References
- Hogg J. On the treatment of diabetes. Lancet. 1852; 59(1479): 6.
- Hofmeister B. Remarks on Diabetes Mellitus, and its Treatment with the Mineral Waters of Carlsbad. BMJ. 1888; 1(1427): 946-49.
- Pavy F.W. Remarks on the Treatment of Diabetes. BMJ. 1869; 1(435): 398.
- Fraser T.R. The Relative Value of Opium, Morphine, and Codeine in Diabetes Mellitus. BMJ. 1889; 1(1464): 118-19.
- Cure of diabetes mellitus with creosote. Lancet. 1834; 22(563): 425.
- Watt R. Cases of diabetes, consumption &: with observations on the history and treatment of disease in general. 1808: 21-2.
- European Society of Cardiology. Vildagliptin shows no adverse effect on ejection fraction in diabetic patients with HF. Hear Fail 2013 Late Break Trial. Доступно на: http://www.escardio.org/congresses/hf2013/congress-to-you/Pages/vildagliptin-shows-no-adverse-effect-ejection-fraction-diabetic-patients-with-heart-failure.aspx. Проверено 03.03.2014.
- Frederich R., Alexander J.H., Fiedorek F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad. Med. 2010; 122(3): 16-27.
- Williams-Herman D., Engel S.S., Round E., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr. Disord. 2010; 10: 7.
- Schweizer A., Dejager S., Foley J.E., Couturier A., Ligueros-Saylan M., Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010; 12(6): 485-94.
- Johansen O.E., Neubacher D., von Eynatten M., Patel S., Woerle H.J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc. Diabetol. 2012; 11: 3.
- Scirica B.M., Bhatt D.L., Braunwald E., et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am. Heart. J. 2011; 162(5): 818-25.e6.
- Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013; 369(14): 1317-26.
- Green J.B., Bethel M.A., Paul S.K., et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am. Heart. J. 2013; 166(6): 983-989.e7.
- U.S. National Institutes of Health. CARMELINA: Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus at high vascular risk (NCT01897532). ClinicalTrials.gov. 2013. Доступно на: http://clinicaltrials.gov/ct2/show/NCT00894868?term=NCT00894868&rank=1. Проверено 03.03.2014.
- U.S. National Institutes of Health. Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure (VIVIDD). ClinicalTrials.gov. 2012.
- Duez H., Cariou B., Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem. Pharmacol. 2012; 83(7): 823-32.
Supplementary files
